Skip to main content
Clinical Trials/NCT05904509
NCT05904509CompletedNot Applicable

The Relationship Between Insulin Resistance and Disease Severity and Duration in Atopic Dermatitis Patients

Bezmialem Vakif University1 site in 1 country32 target enrollmentStarted: September 1, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
32
Locations
1
Primary Endpoint
SCORAD index

Study Overview

Brief Summary

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis.

Detailed Description

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis. EASI and SCORAD values and disease duration of atopic dermatitis patients are calculated during the examination. HOMA-IR blood test result is compared with the results.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Retrospective

Eligibility Criteria

Ages
2 Years to 80 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Atopic dermatitis patients confirmed by a dermatologist

Exclusion Criteria

  • patients younger than 2 years
  • patients older than 80 years
  • Atopic dermatitis patients without HOMA-IR result

Outcomes

Primary Outcomes

SCORAD index

Time Frame: 12 months

Severity scoring of atopic dermatitis is calculated for each patient in the study. 6 intensity items (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, dryness); 2 subjective symptoms(itch, sleeplessness); body surface area are studied. Max score is 103.

HOMA-IR

Time Frame: 12 months

Patients' blood test show the result of fasting insulin (microU/L) x fasting glucose (mmol/L)/22.5

Duration of the disease

Time Frame: 12 months

The time from the first onset of symptoms of the disease to the present. The relationship between insulin resistance and disease duration is examined

EASI index

Time Frame: 12 months

Eczema Area and Severity Index is calculated for each patient in the study. Body surface area, 4 intensity items(erythema, induration, excoriation, lichenification) are studied. Max score is 72.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Insulin Resistance in Atopic Dermatitis... | Clinical Trial